Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 462

1.

Cerebral Blood Perfusion Predicts Response to Sertraline versus Placebo for Major Depressive Disorder in the EMBARC Trial.

Cooper CM, Chin Fatt CR, Jha M, Fonzo GA, Grannemann BD, Carmody T, Ali A, Aslan S, Almeida JRC, Deckersbach T, Fava M, Kurian BT, McGrath PJ, McInnis M, Parsey RV, Weissman M, Phillips ML, Lu H, Etkin A, Trivedi MH.

EClinicalMedicine. 2019 May 18;10:32-41. doi: 10.1016/j.eclinm.2019.04.007. eCollection 2019 Apr.

2.

Fatigue in Nondialysis Chronic Kidney Disease: Correlates and Association with Kidney Outcomes.

Gregg LP, Jain N, Carmody T, Minhajuddin AT, Rush AJ, Trivedi MH, Hedayati SS.

Am J Nephrol. 2019 Jun 5:1-11. doi: 10.1159/000500668. [Epub ahead of print]

PMID:
31167183
3.

Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.

Daly EJ, Trivedi MH, Janik A, Li H, Zhang Y, Li X, Lane R, Lim P, Duca AR, Hough D, Thase ME, Zajecka J, Winokur A, Divacka I, Fagiolini A, Cubala WJ, Bitter I, Blier P, Shelton RC, Molero P, Manji H, Drevets WC, Singh JB.

JAMA Psychiatry. 2019 Jun 5. doi: 10.1001/jamapsychiatry.2019.1189. [Epub ahead of print]

PMID:
31166571
4.

Feasibility and Acceptability of the Youth Aware of Mental Health (YAM) Intervention in US Adolescents.

Lindow JC, Hughes JL, South C, Gutierrez L, Bannister E, Trivedi MH, Byerly MJ.

Arch Suicide Res. 2019 Jun 4:1-30. doi: 10.1080/13811118.2019.1624667. [Epub ahead of print]

PMID:
31159674
5.

When Discontinuing SSRI Antidepressants Is a Challenge: A Response to Letters to the Editor.

Jha MK, Trivedi MH.

Am J Psychiatry. 2019 Jun 1;176(6):488-489. doi: 10.1176/appi.ajp.2019.18121419r. No abstract available.

PMID:
31154822
6.

Acute and long-term cannabis use among stimulant users: Results from CTN-0037 Stimulant Reduction Intervention using Dosed Exercise (STRIDE) Randomized Control Trial.

Vidot DC, Rethorst CD, Carmody TJ, Stoutenberg M, Walker R, Greer TL, Trivedi MH.

Drug Alcohol Depend. 2019 May 7;200:139-144. doi: 10.1016/j.drugalcdep.2019.02.032. [Epub ahead of print]

PMID:
31129484
7.

VitalSign6: A Primary Care First (PCP-First) Model for Universal Screening and Measurement-Based Care for Depression.

Trivedi MH, Jha MK, Kahalnik F, Pipes R, Levinson S, Lawson T, Rush AJ, Trombello JM, Grannemann B, Tovian C, Kinney R, Clark EW, Greer TL.

Pharmaceuticals (Basel). 2019 May 14;12(2). pii: E71. doi: 10.3390/ph12020071.

8.

Childhood trauma history is linked to abnormal brain connectivity in major depression.

Yu M, Linn KA, Shinohara RT, Oathes DJ, Cook PA, Duprat R, Moore TM, Oquendo MA, Phillips ML, McInnis M, Fava M, Trivedi MH, McGrath P, Parsey R, Weissman MM, Sheline YI.

Proc Natl Acad Sci U S A. 2019 Apr 23;116(17):8582-8590. doi: 10.1073/pnas.1900801116. Epub 2019 Apr 8.

9.

Sex differences in the association of baseline c-reactive protein (CRP) and acute-phase treatment outcomes in major depressive disorder: Findings from the EMBARC study.

Jha MK, Minhajuddin A, Chin-Fatt C, Greer TL, Carmody TJ, Trivedi MH.

J Psychiatr Res. 2019 Jun;113:165-171. doi: 10.1016/j.jpsychires.2019.03.013. Epub 2019 Mar 20.

PMID:
30959227
10.
11.

VitalSign: Screening, Diagnosis, and Treatment of Depression for Adolescents Presenting to Pediatric Primary and Specialty Care Settings.

Pop R, Kinney R, Grannemann B, Emslie G, Trivedi MH.

J Am Acad Child Adolesc Psychiatry. 2019 Jun;58(6):632-635. doi: 10.1016/j.jaac.2019.01.019. Epub 2019 Apr 4.

PMID:
30953732
12.

Irritability and Its Clinical Utility in Major Depressive Disorder: Prediction of Individual-Level Acute-Phase Outcomes Using Early Changes in Irritability and Depression Severity.

Jha MK, Minhajuddin A, South C, Rush AJ, Trivedi MH.

Am J Psychiatry. 2019 May 1;176(5):358-366. doi: 10.1176/appi.ajp.2018.18030355. Epub 2019 Mar 29.

PMID:
30922100
13.

50 Adjunctive Buprenorphine/Samidorphan Combination in Patients with Major Depressive Disorder: Phase 3 Long-term Extension Study Results.

Thase M, Stanford AD, Memisoglu A, Martin W, Claxton A, Bodnik JA, Trivedi MH, Fava M, Pathak S.

CNS Spectr. 2019 Feb;24(1):203-204. doi: 10.1017/S1092852919000427.

PMID:
30859977
14.

Adiponectin Moderates Antidepressant Treatment Outcome in the Combining Medications to Enhance Depression Outcomes Randomized Clinical Trial.

Furman JL, Soyombo A, Czysz AH, Jha MK, Carmody TJ, Mason BL, Scherer PE, Trivedi MH.

Pers Med Psychiatry. 2018 Aug-Sep;9-10:1-7. doi: 10.1016/j.pmip.2018.05.001. Epub 2018 Jun 21.

PMID:
30859144
15.

Comparative Efficacy of Therapies for Treatment of Depression for Patients Undergoing Maintenance Hemodialysis: A Randomized Clinical Trial.

Mehrotra R, Cukor D, Unruh M, Rue T, Heagerty P, Cohen SD, Dember LM, Diaz-Linhart Y, Dubovsky A, Greene T, Grote N, Kutner N, Trivedi MH, Quinn DK, Ver Halen N, Weisbord SD, Young BA, Kimmel PL, Hedayati SS.

Ann Intern Med. 2019 Feb 26. doi: 10.7326/M18-2229. [Epub ahead of print]

PMID:
30802897
16.

Pretreatment Rostral Anterior Cingulate Cortex Connectivity With Salience Network Predicts Depression Recovery: Findings From the EMBARC Randomized Clinical Trial.

Whitton AE, Webb CA, Dillon DG, Kayser J, Rutherford A, Goer F, Fava M, McGrath P, Weissman M, Parsey R, Adams P, Trombello JM, Cooper C, Deldin P, Oquendo MA, McInnis MG, Carmody T, Bruder G, Trivedi MH, Pizzagalli DA.

Biol Psychiatry. 2019 May 15;85(10):872-880. doi: 10.1016/j.biopsych.2018.12.007. Epub 2018 Dec 19.

PMID:
30718038
17.

Anxiety and anhedonia in depression: Associations with neuroticism and cognitive control.

Liao A, Walker R, Carmody TJ, Cooper C, Shaw MA, Grannemann BD, Adams P, Bruder GE, McInnis MG, Webb CA, Dillon DG, Pizzagalli DA, Phillips ML, Kurian BT, Fava M, Parsey RV, McGrath PJ, Weissman MM, Trivedi MH.

J Affect Disord. 2019 Feb 15;245:1070-1078. doi: 10.1016/j.jad.2018.11.072. Epub 2018 Nov 14.

PMID:
30699849
18.

Can targeted metabolomics predict depression recovery? Results from the CO-MED trial.

Czysz AH, South C, Gadad BS, Arning E, Soyombo A, Bottiglieri T, Trivedi MH.

Transl Psychiatry. 2019 Jan 16;9(1):11. doi: 10.1038/s41398-018-0349-6.

19.

The Stimulant Selective Severity Assessment: A replication and exploratory extension of the Cocaine Selective Severity Assessment.

Walker R, Northrup TF, Tillitski J, Bernstein I, Greer TL, Trivedi MH.

Subst Use Misuse. 2019;54(3):351-361. doi: 10.1080/10826084.2018.1467453. Epub 2019 Jan 18.

PMID:
30657406
20.

The Concise Health Risk Tracking-Self Report: Psychometrics within a placebo-controlled antidepressant trial among depressed outpatients.

Trombello JM, Killian MO, Grannemann BD, Rush AJ, Mayes TL, Parsey RV, McInnis M, Jha MK, Ali A, McGrath PJ, Adams P, Oquendo MA, Weissman MM, Carmody TJ, Trivedi MH.

J Psychopharmacol. 2019 Feb;33(2):185-193. doi: 10.1177/0269881118817156. Epub 2019 Jan 17.

PMID:
30652941
21.

Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression.

Freeman MP, Papakostas GI, Hoeppner B, Mazzone E, Judge H, Cusin C, Mathew S, Sanacora G, Iosifescu D, DeBattista C, Trivedi MH, Fava M.

J Psychiatr Res. 2019 Mar;110:166-171. doi: 10.1016/j.jpsychires.2019.01.010. Epub 2019 Jan 8.

PMID:
30641350
22.

Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).

Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI.

Mol Psychiatry. 2019 Jan 7. doi: 10.1038/s41380-018-0311-2. [Epub ahead of print]

PMID:
30617276
23.

Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression.

Salloum NC, Fava M, Freeman MP, Flynn M, Hoeppner B, Hock RS, Cusin C, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, Debattista C, Ionescu DF, Papakostas GI.

Depress Anxiety. 2019 Mar;36(3):235-243. doi: 10.1002/da.22875. Epub 2018 Dec 30.

PMID:
30597688
24.

When Discontinuing SSRI Antidepressants Is a Challenge: Management Tips.

Jha MK, Rush AJ, Trivedi MH.

Am J Psychiatry. 2018 Dec 1;175(12):1176-1184. doi: 10.1176/appi.ajp.2018.18060692. No abstract available.

PMID:
30501420
25.

Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies.

Fava M, Thase ME, Trivedi MH, Ehrich E, Martin WF, Memisoglu A, Nangia N, Stanford AD, Yu M, Pathak S.

Mol Psychiatry. 2018 Oct 29. doi: 10.1038/s41380-018-0284-1. [Epub ahead of print] No abstract available.

PMID:
30374191
26.

The Concise Health Risk Tracking Self-Report (CHRT-SR) assessment of suicidality in depressed outpatients: A psychometric evaluation.

De La Garza N, Rush AJ, Killian MO, Grannemann BD, Carmody TJ, Trivedi MH.

Depress Anxiety. 2019 Apr;36(4):313-320. doi: 10.1002/da.22855. Epub 2018 Oct 29.

PMID:
30370613
27.

Pharmacogenomics and Biomarkers of Depression.

Jha MK, Trivedi MH.

Handb Exp Pharmacol. 2019;250:101-113. doi: 10.1007/164_2018_171.

PMID:
30341727
28.

Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).

Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI.

Mol Psychiatry. 2018 Oct 3. doi: 10.1038/s41380-018-0256-5. [Epub ahead of print] Erratum in: Mol Psychiatry. 2019 Jan 7;:.

29.

Resting EEG Measures of Brain Arousal in a Multisite Study of Major Depression.

Ulke C, Tenke CE, Kayser J, Sander C, Böttger D, Wong LYX, Alvarenga JE, Fava M, McGrath PJ, Deldin PJ, Mcinnis MG, Trivedi MH, Weissman MM, Pizzagalli DA, Hegerl U, Bruder GE.

Clin EEG Neurosci. 2019 Jan;50(1):3-12. doi: 10.1177/1550059418795578. Epub 2018 Sep 5.

PMID:
30182751
30.

Toward a very brief quality of life enjoyment and Satisfaction Questionnaire.

Rush AJ, South CC, Jha MK, Grannemann BD, Trivedi MH.

J Affect Disord. 2019 Jan 1;242:87-95. doi: 10.1016/j.jad.2018.08.052. Epub 2018 Aug 15.

PMID:
30173063
31.

Experimental Therapies for Treatment-Resistant Depression: "How do you decide when to go to an unproven or experimental therapy with patients that are treatment-resistant depression?"

Jha MK, Trivedi MH.

Focus (Am Psychiatr Publ). 2018 Jul;16(3):279-284. doi: 10.1176/appi.focus.20180013. Epub 2018 Jul 18. No abstract available.

PMID:
30147629
32.

Do baseline sub-threshold hypomanic symptoms affect acute-phase antidepressant outcome in outpatients with major depressive disorder? Preliminary findings from the randomized CO-MED trial.

Jha MK, Malchow AL, Grannemann BD, Rush AJ, Trivedi MH.

Neuropsychopharmacology. 2018 Oct;43(11):2197-2203. doi: 10.1038/s41386-018-0180-z. Epub 2018 Aug 15.

PMID:
30135556
33.

Development and evaluation of a multimodal marker of major depressive disorder.

Yang J, Zhang M, Ahn H, Zhang Q, Jin TB, Li I, Nemesure M, Joshi N, Jiang H, Miller JM, Ogden RT, Petkova E, Milak MS, Sublette ME, Sullivan GM, Trivedi MH, Weissman M, McGrath PJ, Fava M, Kurian BT, Pizzagalli DA, Cooper CM, McInnis M, Oquendo MA, Mann JJ, Parsey RV, DeLorenzo C.

Hum Brain Mapp. 2018 Nov;39(11):4420-4439. doi: 10.1002/hbm.24282. Epub 2018 Aug 16.

PMID:
30113112
34.

A Novel Strategy to Identify Placebo Responders: Prediction Index of Clinical and Biological Markers in the EMBARC Trial.

Trivedi MH, South C, Jha MK, Rush AJ, Cao J, Kurian B, Phillips M, Pizzagalli DA, Trombello JM, Oquendo MA, Cooper C, Dillon DG, Webb C, Grannemann BD, Bruder G, McGrath PJ, Parsey R, Weissman M, Fava M.

Psychother Psychosom. 2018;87(5):285-295. doi: 10.1159/000491093. Epub 2018 Aug 15.

PMID:
30110685
35.

The Promoting Activity in Cancer Survivors (PACES) trial: a multiphase optimization of strategy approach to increasing physical activity in breast cancer survivors.

Rethorst CD, Hamann HA, Carmody TJ, Sharp KJ, Argenbright KE, Haley BB, Skinner CS, Trivedi MH.

BMC Cancer. 2018 Jul 18;18(1):744. doi: 10.1186/s12885-018-4662-5.

36.

Association of Novel ALX4 Gene Polymorphisms with Antidepressant Treatment Response: Findings from the CO-MED Trial.

Gadad BS, Raj P, Jha MK, Carmody T, Dozmorov I, Mayes TL, Wakeland EK, Trivedi MH.

Mol Neuropsychiatry. 2018 Jun;4(1):7-19. doi: 10.1159/000487321. Epub 2018 May 3.

37.

Improving the identification and treatment of depression in low-income primary care clinics: a qualitative study of providers in the VitalSign6 program.

Kahalnik F, Sanchez K, Faria A, Grannemann B, Jha M, Tovian C, Clark EW, Levinson S, Pipes R, Pederson M, Trivedi MH.

Int J Qual Health Care. 2019 Feb 1;31(1):57-63. doi: 10.1093/intqhc/mzy128.

PMID:
29982702
38.

Personalized prediction of antidepressant v. placebo response: evidence from the EMBARC study.

Webb CA, Trivedi MH, Cohen ZD, Dillon DG, Fournier JC, Goer F, Fava M, McGrath PJ, Weissman M, Parsey R, Adams P, Trombello JM, Cooper C, Deldin P, Oquendo MA, McInnis MG, Huys Q, Bruder G, Kurian BT, Jha M, DeRubeis RJ, Pizzagalli DA.

Psychol Med. 2019 May;49(7):1118-1127. doi: 10.1017/S0033291718001708. Epub 2018 Jul 2.

PMID:
29962359
39.

Statistical harmonization corrects site effects in functional connectivity measurements from multi-site fMRI data.

Yu M, Linn KA, Cook PA, Phillips ML, McInnis M, Fava M, Trivedi MH, Weissman MM, Shinohara RT, Sheline YI.

Hum Brain Mapp. 2018 Nov;39(11):4213-4227. doi: 10.1002/hbm.24241. Epub 2018 Jul 1.

PMID:
29962049
40.

Association of Midlife Cardiorespiratory Fitness With Incident Depression and Cardiovascular Death After Depression in Later Life.

Willis BL, Leonard D, Barlow CE, Martin SB, DeFina LF, Trivedi MH.

JAMA Psychiatry. 2018 Sep 1;75(9):911-917. doi: 10.1001/jamapsychiatry.2018.1467.

PMID:
29955781
41.

Association of T and non-T cell cytokines with anhedonia: Role of gender differences.

Jha MK, Miller AH, Minhajuddin A, Trivedi MH.

Psychoneuroendocrinology. 2018 Sep;95:1-7. doi: 10.1016/j.psyneuen.2018.05.017. Epub 2018 May 12.

PMID:
29783087
42.

Characterizing anxiety subtypes and the relationship to behavioral phenotyping in major depression: Results from the EMBARC study.

Trombello JM, Pizzagalli DA, Weissman MM, Grannemann BD, Cooper CM, Greer TL, Malchow AL, Jha MK, Carmody TJ, Kurian BT, Webb CA, Dillon DG, McGrath PJ, Bruder G, Fava M, Parsey RV, McInnis MG, Adams P, Trivedi MH.

J Psychiatr Res. 2018 Jul;102:207-215. doi: 10.1016/j.jpsychires.2018.04.003. Epub 2018 Apr 6.

PMID:
29689518
43.

A Complier Average Causal Effect Analysis of the Stimulant Reduction Intervention using Dosed Exercise Study.

Carmody T, Greer TL, Walker R, Rethorst CD, Trivedi MH.

Contemp Clin Trials Commun. 2018 Jun;10:1-8. doi: 10.1016/j.conctc.2018.02.001.

44.

Psychometric properties of the concise health risk tracking (CHRT) in adolescents with suicidality.

Mayes TL, Kennard BD, Killian M, Carmody T, Grannemann BD, Rush AJ, Jha MK, Hughes J, Emslie GJ, Trivedi MH.

J Affect Disord. 2018 Aug 1;235:45-51. doi: 10.1016/j.jad.2018.03.007. Epub 2018 Mar 26.

PMID:
29649710
45.

Pretreatment Rostral Anterior Cingulate Cortex Theta Activity in Relation to Symptom Improvement in Depression: A Randomized Clinical Trial.

Pizzagalli DA, Webb CA, Dillon DG, Tenke CE, Kayser J, Goer F, Fava M, McGrath P, Weissman M, Parsey R, Adams P, Trombello J, Cooper C, Deldin P, Oquendo MA, McInnis MG, Carmody T, Bruder G, Trivedi MH.

JAMA Psychiatry. 2018 Jun 1;75(6):547-554. doi: 10.1001/jamapsychiatry.2018.0252.

46.

A psychometric evaluation of the Concise Health Risk Tracking Self-Report (CHRT-SR)- a measure of suicidality-in patients with stimulant use disorder.

Sanchez K, Killian MO, Mayes TL, Greer TL, Trombello JM, Lindblad R, Grannemann BD, Carmody TJ, Rush AJ, Walker R, Trivedi MH.

J Psychiatr Res. 2018 Jul;102:65-71. doi: 10.1016/j.jpsychires.2018.03.012. Epub 2018 Mar 27.

PMID:
29626753
47.

Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: Findings from CO-MED trial.

Jha MK, Wakhlu S, Dronamraju N, Minhajuddin A, Greer TL, Trivedi MH.

J Affect Disord. 2018 Jul;234:34-37. doi: 10.1016/j.jad.2018.02.089. Epub 2018 Feb 27.

PMID:
29522941
48.

Antisuicidal Effects of Ketamine: A Promising First Step.

Trivedi MH.

Am J Psychiatry. 2018 Feb 1;175(2):97-98. doi: 10.1176/appi.ajp.2017.17111261. No abstract available.

PMID:
29385830
49.

Personalized Antidepressant Selection and Pathway to Novel Treatments: Clinical Utility of Targeting Inflammation.

Jha MK, Trivedi MH.

Int J Mol Sci. 2018 Jan 12;19(1). pii: E233. doi: 10.3390/ijms19010233. Review.

50.

Psychometrics of the Self-Report Concise Associated Symptoms Tracking Scale (CAST-SR): Results From the STRIDE (CTN-0037) Study.

Trombello JM, Killian MO, Liao A, Sanchez K, Greer TL, Walker R, Grannemann B, Rethorst CD, Carmody T, Trivedi MH.

J Clin Psychiatry. 2018 Mar/Apr;79(2). pii: 17m11707. doi: 10.4088/JCP.17m11707.

Supplemental Content

Loading ...
Support Center